RECURRENT CHOLANGIOCARCINOMA
Clinical trials for RECURRENT CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bile duct cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or come back. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. The main goal is to see how many pa…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated May 17, 2026 04:32 UTC
-
New hope for Hard-to-Treat cancers: olaparib targets IDH mutations
Disease control OngoingThis study tests the drug olaparib in people with advanced solid tumors (including brain tumors and bile duct cancer) that have IDH1 or IDH2 mutations. The goal is to see if olaparib can shrink or slow the growth of these cancers. About 89 participants will receive the drug, and …
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New drug combo targets tough cancers: hope for liver, pancreas, and bile duct tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The main goals are to find the safest dose and see if the drugs can shrink tumors. About 55 particip…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 12, 2026 13:42 UTC